Longitudinal studies demonstrate that decrease in adipocyte size that accompanies weight loss associates with improved obesity-related disease endpoints in some (Table 1, tier 2), though not all studies (48, 49), and pioglitazone treatment actually induced improved insulin sensitivity that associated with increase, not decrease, in adipocyte size (50). This evidence concerns the gene INS and obesity disorder.